Mitchel Berger, MD


My research and its relevance to stem cell research is multifaceted. I am involved with the Molecular Marker Core in our department in terms of correlative biology and outcome of patients with both low-grade and high-grade gliomas. I am also involved in the Molecular Imaging Program, in which we correlate tissue samples with imaging-based biopsies to develop a panel of surrogate imaging markers for various biological processes that result in tumor growth, angiogenesis, etc. The other aspect of my research involves drug delivery, and to this end I have been part of the team that is developing nanoliposomes for treatment of malignant brain tumors. We have already developed a CPT-11 construct that we ve tested in canine models, using convection-enhanced delivery, and have been given FDA approval to bring this back for a clinical trial in brain tumors. Also, my research has involved DNA damage and repair mechanisms in gliomas, especially as it relates to alkyltransferase levels and promotor methylation of the MGMT gene in response to alkylating agents such as temozolomide.